Revista Española de Medicina Nuclear e Imagen Molecular, published by Elsevier España SLU, stands as a vital resource in the field of Radiology, Nuclear Medicine, and Molecular Imaging. With an ISSN of 2253-654X, this journal is committed to disseminating high-quality research and advancements in clinical practices, aiming to bridge the gap between theoretical research and application in healthcare. Operating since 2012, it features a robust archive of peer-reviewed articles and case studies, although it currently holds a Q4 ranking in the Scopus category, indicating significant potential for growth and influence within the academic community. The journal is indexed in Scopus, with a rank of 255 out of 333, placing it in the 23rd percentile, which underlines the need for increased contributions from researchers eager to enhance its standing. While it is not an open-access journal, its availability through libraries and institutions ensures that a wide audience can access critical findings and innovations in the rapidly evolving field of nuclear medicine. As we look towards the convergence period from 2012 to 2024, Revista Española de Medicina Nuclear e Imagen Molecular aspires to fortify its role as a cornerstone for collaboration and advancement in nuclear imaging and radiology.

EJNMMI Radiopharmacy and Chemistry, published by SpringerNature, stands at the forefront of research in the critical fields of radiopharmacy and nuclear medicine. With an impressive impact factor and a dedicated Open Access policy since 2016, this journal invites the global scientific community to share advancements in the synthesis, development, and application of radiopharmaceuticals within the realm of analytical chemistry and pharmacology. As evidenced by its notable categorizations, including Q1 in Analytical Chemistry and Radiology, Nuclear Medicine and Imaging, along with high Scopus rankings, EJNMMI offers a prestigious platform for rigorous peer-reviewed research that informs and inspires progress in medical imaging and therapeutics. The journal's commitment to accessibility fosters collaboration and innovation, making it an essential resource for researchers, medical professionals, and students seeking to advance their understanding and application of radiopharmaceuticals.

Molecular Imaging is a prominent journal published by SAGE Publications Inc., which serves as a vital platform for the dissemination of high-quality research in the field of molecular imaging. With an E-ISSN of 1536-0121, this journal has established itself within several key areas, including Biomedical Engineering, Biotechnology, Condensed Matter Physics, Molecular Medicine, and Radiology, Nuclear Medicine and Imaging. Spanning from 2002 to 2024 and currently classified within the prestigious Q2 and Q3 quartiles, Molecular Imaging aims to highlight the latest developments and innovative methodologies in molecular imaging techniques and applications. Researchers from diverse backgrounds will find the journal's content valuable for staying updated with recent advancements, evidenced by its competitive Scopus ranking and a commitment to fostering interdisciplinary collaboration. Although the journal is not open access, the rigorous peer-review process ensures that all published articles provide significant contributions to the field, making it an essential resource for professionals, researchers, and students alike.

Welcome to Seminars in Nuclear Medicine, a prestigious journal published by W B Saunders Co-Elsevier Inc that has been at the forefront of the field since its inception in 1971. This journal serves as a dedicated forum for researchers, healthcare professionals, and students specializing in the rapidly evolving areas of radiology and nuclear medicine. With an impressive ranking of #29 out of 333 in the Scopus category, drawing an esteemed 91st percentile, it holds a distinguished Q1 category status, highlighting its critical role in disseminating high-quality research and clinical practices. Although it does not operate as an Open Access publication, Seminars in Nuclear Medicine remains a vital resource, featuring comprehensive reviews and insightful articles that inform the medical community about the latest advancements and applications within nuclear imaging. This journal not only enhances knowledge but also encourages collaboration among professionals dedicated to improving patient outcomes through innovative nuclear medicine techniques.

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

Hong Kong Journal of Radiology, an esteemed publication of the Hong Kong Academy of Medicine Press, serves as a vital platform for disseminating innovative research in the field of radiology, nuclear medicine, and imaging. Established in 2011 and operating under an Open Access model since 2018, this journal not only promotes the sharing of knowledge but also enhances global accessibility to cutting-edge studies. With its ISSN 2223-6619 and E-ISSN 2307-4620, the journal strives to engage a diverse audience ranging from experienced professionals to aspiring scholars in the medical imaging domain. Despite its current ranking in the Q4 quartile of the Scopus category for radiology, the journal is committed to improving its standing by featuring high-quality research that addresses pressing issues in the field. The journal's convergence from 2011 to 2024 reflects its ongoing dedication to fostering academic excellence and encouraging collaborative discourse among researchers and practitioners globally. Located in Hong Kong, the journal plays a significant role in shaping the future of radiology education and practice in China and beyond.

EJNMMI Research, a prominent journal published by Springer, plays a pivotal role in advancing the fields of radiology, nuclear medicine, and imaging. With an impact factor that reflects its strong standing—ranking in the top 22% of its category (Q1 as of 2023)—this open-access journal offers researchers, professionals, and students unparalleled access to innovative research and developments in the field since its inception in 2011. Based in Germany, EJNMMI Research fosters global collaboration by ensuring that cutting-edge findings are freely accessible, thereby accelerating scientific discovery and application. With an emphasis on high-quality, peer-reviewed articles, it serves as an essential resource for those seeking to stay at the forefront of nuclear medicine and imaging. By bridging theoretical insights with practical applications, the journal not only influences academic discourse but also supports ongoing advancements in clinical practices.

Theranostics is a premier journal in the field of Medicine and Pharmacology, published by IVYSPRING INT PUBL. With its commitment to open access since 2011, it facilitates the widespread dissemination of innovative research, fostering collaboration and advancements in therapeutic diagnostics. The journal proudly holds a Q1 ranking in both Medicine (Miscellaneous) and Pharmacology, Toxicology and Pharmaceutics, as of 2023, showcasing its esteemed position within the scientific community. Recognized globally, it ranks in the top 1%, with Scopus rankings placing it as 4th out of 398 in Medicine and 1st out of 43 in Pharmacology. Theranostics serves as a crucial platform for researchers, professionals, and students to explore cutting-edge developments as it converges multidisciplinary approaches to enhance patient care and treatment efficacy. With a focus on bridging experimental research and clinical applications, the journal is instrumental in shaping future therapies and diagnostic strategies.

Medicine Nucleaire-Imagerie Fonctionnelle et Metabolique is a prominent journal published by Elsevier France-Editions Scientifiques Medicales Elsevier, dedicated to the specialized fields of nuclear medicine and functional imaging. With an ISSN of 0928-1258 and an E-ISSN of 1878-6820, this esteemed publication has been a crucial platform for the dissemination of research and developments in the discipline since its inception in 1993. Covering a wide array of topics within biophysics, radiological and ultrasound technology, and radiology, the journal currently holds a Q4 category ranking in these fields, reflecting its significance within the academic community. Although there are currently no open access options available for readers, the journal caters to a niche audience of researchers, professionals, and students who seek to enhance their understanding of metabolic imaging and its applications. The 2023 Scopus ranks indicate its position as an emerging source of knowledge in a competitive landscape, making it an important resource for the latest studies and innovations in nuclear medicine.

Welcome to MOLECULAR IMAGING AND BIOLOGY, an esteemed journal published by SPRINGER that delves into the rapidly advancing fields of molecular imaging and its applications in biology, with a strong emphasis on cancer research, oncology, and radiology. With ISSN 1536-1632 and E-ISSN 1860-2002, this journal has established itself as a prominent platform for disseminating insightful research and innovative methodologies since its inception in 2002. As of 2023, it holds commendable rankings in notable categories—Q3 in Cancer Research, Q2 in Oncology, and Q2 in Radiology, Nuclear Medicine, and Imaging—illustrating its impact and relevance in these disciplines. Furthermore, with impressive Scopus rankings placing it in the top quartile of journals within its categories, it serves as an essential resource for researchers, professionals, and students seeking to stay informed about the latest developments in molecular imaging technologies and biological applications. While currently not an Open Access journal, the rigorous peer-review process ensures high-quality and impactful contributions to the field, making it a valuable addition to any academic library.